

FOCUSED ON ACTIONABLE RESULTS

30 cancer-associated genes, 23 exons and 146 hotspots.

The FOLLOW IT panel maximizes treatment options by:

- Focusing on clinically actionable sensitizing and resistance mutations within a carefully selected set of hotspots.
- Keeping the panel small, focused and robust also provides a cost-effective solution.

Gene Content & Associated Treatment Options Genes and Associated Cancers

Gene	Position	Therapeutic Options
AKT1	E17	●
ALK	T1151, L1152, C1156, F1174, L1196, L1198, G1202, O1203, S1206, G1269, R1275	● ● ● ●
AR	L702H, S741, W742, V716, H875, F877, T878	● ●
BRAF	Q201, G466, F468, G469, Y472, D594, G596, L597, V600, K601	● ● ● ●
CTNNB1	D32, S33, G34, S37, T41, S45	●
DDR2	L239, I638, S768	● ● ●
EGFR	S492, Exon18, Exon19, Exon20, Exon21	● ● ● ●
ERBB2	G309, S310, L755, C805, Exon20	● ● ●
ESR1	K303, S463, V534, P535, L536, Y537, D538	● ●
GNA11	Q209	●
GNAQ	Q209	●
GNAS	R201	●
HRAS	G12, G13, Q61	● ●
IDH1	R132	●
IDH2	R140, R172	●
KIT	Exon9, Exon11, Exon13, T670, D816, D820, N822, Y823, A829	● ● ● ●
KRAS	G12, G13, A59, Q61, K117, A146	● ● ● ●
MAP2K1(MEK1)	Q56, K57, K59, D67, C121, P124, P387	● ● ●
MAP2K2(MEK2)	F57, Q60, K61, L119	● ● ●
MET	Y1253, Exon13, Exon14 (-50 to +25), Exon18	● ● ●
NRAS	G12, G13, A59, Q61, K117, A146	● ● ● ●
PDGFRA	N659, R560-E571, D842, L839-Y849	● ● ●
PIK3CA	R88, E542, E545, Q546, D549, M1043, N1044, A1046, H1047, G1049	● ● ●
POLE	Exon9, Exon10, Exon11, Exon12, Exon13, Exon14	●
PTCH1	W844, G1093	● ● ●
PTEN	R130	● ● ●
RET	C634, V804, M918	● ● ● ●
ROS1	L2026, G2032	● ●
SMO	D473, S533, W535	● ●
TP53	Exon4, Exon5, Exon6, Exon7, Exon8, Exon9	

Cancer	Associated Genes
Basal Cell Carcinoma	PTCH1, SMO
Bladder Cancer	HRAS, PIK3CA
Breast Cancer	AKT1, BRAF, DDR2, ERBB2 (HER2), ESR1, PIK3CA, PTEN
Colorectal Cancer	AKT1, BRAF, CTNNB1, EGFR, KRAS, MET, NRAS, PIK3CA, PTEN, POLE
Endometrial Cancer	CTNNB1, DDR2, PIK3CA, PTEN, POLE
GIST	BRAF, KIT, PDGFRA
Glioma	BRAF, EGFR, IDH1, IDH2, PIK3CA, PTEN, SMO
Head and Neck Cancer	BRAF, DDR2, PIK3CA
Lung Cancer	AKT1, ALK, BRAF, DDR2, EGFR, ERBB2, KRAS, MAP2K1, MET, NRAS, PIK3CA, PTEN, ROS1
Melanoma	BRAF, CTNNB1, GNA11, GNAQ, KIT, MAP2K1, NRAS
Neuroblastoma	ALK
Ovarian Cancer	BRAF, CTNNB1, KRAS, NRAS, PIK3CA, PTEN
Pancreatic Cancer	CTNNB1, KRAS
Prostate Cancer	AR, DDR2, KRAS, PTEN
Thymic Cancer	KIT
Thyroid Cancer	BRAF, CTNNB1, HRAS, KRAS, NRAS, TER

Key	On-Label Drugs	Off-Label Drugs	Clinical Trial	Resistance
	●	●	●	●

Please note:
 The genes on the panel are under continuous review and are subject to change.
 The therapeutic options are under continuous review by the FDA, NCCN and other literature and are subject to change.